I-Corps 10/11/2011

Advanced Chemistry for Pharmaceutical Progress

Team: Kiel Neumann (EL)

Stephen DiMagno (PI)

Allan Green (Mentor)

I-Corps 10/11/112

PET is a non-invasive medical diagnostic technique for cardiac, brain, and tumor imaging

GFP technology makes new (unknown) and known (but clinically inaccessible) [18F]-labeled radiotracers readily available

Fast, multiplatform, high efficiency synthesis of these fleeting, precious agents.

Initial target indications: pediatric neuroblastoma, Parkinson’s disease.

General methodology for adding fluorine

to lead compounds of

interest

General methodology for adding fluorine

to lead compounds of

interest

The Business Model Canvas

Accessibility (RCY)PuritySpeedPET/SPECTMultiplatformSensitivity (nca)Specific compounds

IPPoP dataRegulatory planUnderstanding of the regulatory process

Contract cGMP precursor manufactureSalary, RentsClinical trials

SOPs for precursors and drugsRecruit clinical sitesIn vivo animal studiesDevelop regulatory plan for pre IND meetingID cGMP CROFund-raising

cGMP manufacturerRadiopharmaciesNuclear Medicine and Radiology departments

Technical Assistance (Image Atlas)FDA regulatory support

Radiopharmacies

Equipment producers

Prescribing physicians

Radiologist who perform studies

Sales of intermediates

Technology license

Product license (royalty)

Direct sales of precursor

R&D and clinical studies presented in journals and meetings

Drug developers

Pharmaceutical development companies

IPPoP data

Radiologists

Technical assistance

- Face to face with attending Radiologist at Stanford University

- Face to face with radiopharmacist at UCSF

- Conference call with Nuclear Radiologist at Memorial Sloan Kettering

- Conference call with president of medium size drug company with PET product at the FDA

- Telephone conference with cGMP facility

I-Corps 10/12/11 5

I-Corps 10/12/11 6

- Immediate need for our product

- Currently used SPECT product for neuroblastoma is limited by absence of correlative CT data

- Our lead PET agent would provide more information on existing imaging equipment base

- Two customers offered to participate in clinical trials

- Potential for further development of other tracers identified in interviews

- Actual need for the general procedure

- Allow access to previously unknown tracers

-Initially seeking to market method technology

-too diffuse, but many opportunities (i.e. product-driven opportunities more than general technology-driven)

-Need to identify specific imaging product opportunities

-Validated hypothesis for immediate need of tracers

-Raised question on identity of lead compound pipeline for Parkinson’s disease

-Recruited two potential partners for clinical trials

7

I-Corps 10/11/11 8

Approximately 2.2 million procedures in the US.

Drug costs range from $700 (on-patent) to ~$150 (generic FDG)

US sales of radiopharmaceuticals for PET and SPECT $1.2 billion

US sales expected to grow to $6 billion by 2018

Global numbers approximately 2x

Source: Bio-Tech Systems Report #330; data for 2010.

I-Corps 10/11/11 9

2500 installed PET scannersPET radiopharmacies cover the entire US marketRadiopharmacies have an interest in proprietary agents as a basis of competition in their market.

I-Corps 10/11/11 10

Neuroblastoma

Prevalence: about 6000 US cases about 1000 new cases per year

Subjects receive 3-6 images/yearto follow response to therapeutic protocols

World market at U.S. x 2 gives potential of 40,000-70,000 scans/year

Drug costs $500/per gives ~$20 - $35 M

Parkinson’s Disease

DatSCAN sales in Europe ~$100 M

The world's highest recorded prevalence of Parkinson's Disease of any region is in Nebraska, with 329.3 people per 100,000 population

US – 600,000 patients 1 scan per year @ $500 = $300 M